Dextrofemine

Dextrofemine

SCHEMBL26845

CC(COc1ccccc1)NC(C)Cc1ccccc1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 9/20 0.59
MAOA P21397 1/20 0.59
PTGS1 P23219 1/20 0.59
MTNR1A P48039 3/20 0.53
MTNR1B P49286 3/20 0.53
TAAR1 Q96RJ0 2/20 0.52
SLC18A2 Q05940 1/20 0.52
HIF1A Q16665 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP1A2 P05177 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
CYP2D6 P10635 1/20 0.51
DRD1 P21728 1/20 0.51
SLC6A2 P23975 1/20 0.51
SLC6A4 P31645 1/20 0.51
CYP2C19 P33261 1/20 0.51
ADRA1A P35348 1/20 0.51
OPRM1 P35372 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dextrofemine SCHEMBL1697215 0.89 TAAR1 (0.58) SIGMAR1MAOAPTGS1MTNR1AMTNR1B
SCHEMBL21243273 0.83 SIGMAR1 (0.73) SIGMAR1MAOATAAR1SLC18A2MEN1
SCHEMBL11876569 0.82 RAB9A (0.51) SIGMAR1MTNR1AMTNR1BMEN1KMT2A
SCHEMBL13996939 0.82 MAOA (0.67) MAOAPTGS1MTNR1AMTNR1BHIF1A
SCHEMBL10883594 0.79 MAOA (0.54) SIGMAR1MAOAPTGS1MTNR1AMTNR1B
SCHEMBL15130914 0.77 MAOA (0.61) SIGMAR1MAOAPTGS1MTNR1AMTNR1B
SCHEMBL27890941 0.77 MAOA (0.61) SIGMAR1MAOAPTGS1MTNR1AMTNR1B
SCHEMBL13212031 0.76 MAOA (0.69) SIGMAR1MAOAPTGS1MTNR1AMTNR1B
SCHEMBL28530803 0.76 SIGMAR1 (0.63) SIGMAR1TAAR1SLC18A2MEN1KMT2A
SCHEMBL11598862 0.76 MAOA (0.69) SIGMAR1MAOAPTGS1MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1879578-A4 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV PHARMACEUTICAL INC (US) 2009-05-13 EP claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
EP-1879578-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV Pharmaceutical Inc. (US) 2008-01-23 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2006102029-A9 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV PHARMACEUTICAL INC (US) 2006-12-07 WO claimed
WO-2006102029-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV PHARMACEUTICAL, INC. (US) 2006-09-28 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-4168092-B1 BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY BARD INC C R (US) 2026-05-27 EP disclosed
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors REGENERON PHARMA (US) 2026-04-09 US disclosed
US-12472241-B2 Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors REGENERON PHARMACEUTICALS, INC. (US) 2025-11-18 US disclosed
EP-0737066-A1 TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER NOVEN PHARMACEUTICALS, INC. (US) 1996-10-16 EP disclosed
US-5446070-A Flexible, finite, bioadhesive, therapeutical agent in solid form NOVER PHARMACEUTICALS, INC. (US) 1995-08-29 US disclosed
WO-1995018603-A1 TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER NOVEN PHARMACEUTICALS, INC. (US) 1995-07-13 WO disclosed
US-3959359-A VASODILATORS LABORATOIRES LAROCHE NAVARRON (FR) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors ALOX15, ALOX15B, ALOX5 SIGMAR1 4382/4885MAOA 644/4885PTGS1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.